Neuropace, Inc. (NPCE) Dividend History

NeuroPace, Inc. (NPCE) is a medical device company specializing in the development and commercialization of responsive neurostimulation systems for the treatment of neurological disorders, primarily epilepsy. Their flagship product, the RNS System, is designed to detect and respond to abnormal brain activity in real-time, aiming to reduce seizure frequency and improve patient quality of life. Founded in 1997, NeuroPace focuses on innovations in neuromodulation technology to address unmet needs in neurological healthcare.

455 N. Bernardo Avenue, Mountain View, CA, 94043
Phone: (650) 237-2700
Website: https://www.neuropace.com

Dividend History

Neuropace, Inc. currently does not pay dividends

Company News

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE

NeuroPace, Inc. (NPCE) announced that its NAUTILUS study did not reach statistical significance for the primary effectiveness endpoint, causing its stock price to fall 28.39%. Pomerantz LLP is investigating potential securities fraud or other unlawful business practices by the company and its officers.

GlobeNewswire Inc.
UPDATE – NeuroPace to Present at the Leerink Partners Global Healthcare Conference

NeuroPace, a medical device company focused on epilepsy treatment, announced that its management team will present at the Leerink Partners 2025 Global Healthcare Conference.

GlobeNewswire Inc.
Neuroscience Market Projected to Reach USD 50.2 Billion by 2032, Growing at a 4.0% CAGR – S&S Insider

The neuroscience market is rapidly expanding, driven by growing awareness of neurological disorders and advancements in medical research and technology. Key investments from public and private sectors, along with the integration of advanced technologies like Brain-Computer Interfaces, AI, and machine learning, are transforming the neuroscience landscape and creating new market opportunities.

GlobeNewswire Inc.

Featured Companies: ABBV ABT BAX BIIB BSX GEHC ILMN JNJ MDT SYK
Globus Medical (GMED) Q1 Earnings and Revenues Beat Estimates

Globus Medical (GMED) delivered earnings and revenue surprises of 30.91% and 3.41%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research

Featured Companies: GMED
NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024

MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of 2024 after market close on Wednesday, May 8, 2024. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 10:26:24 UTC